Jack U. Flanagan

TL;DR: A screen identifies a drug that specifically kills glycolysis-dependent cancer cells by inhibiting glucose uptake and identifies a class of compounds, the 3-series, exemplified by STF-31, which selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells onGLUT1 for survival.

TL;DR: Results show that inhibition of p110α alone has the potential to block growth factor signalling and reduce growth in a subset of tumours.

TL;DR: A structure-activity relationship study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) identified substitution at the 4 and 6 positions of the benzimdazole ring as having significant effects on the potency of substituted derivatives.

TL;DR: The X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR, which shows a 200-fold selectivity for T790M/L858R over wildtype EGFR.

TL;DR: Latexin is expressed in the developing brain, and it is found that it plays a role in inflammation, as it is expressed at high levels and is inducible in macrophages in concert with other protease inhibitors and potential protease targets.